公开(公告)号：WO2012009534A3

公开(公告)日：2012-03-29

申请号：PCT/US2011044004

申请日：2011-07-14

Applicant: REVELC LLC ,  COE JOTHAM WADSWORTH ,  GRAY DAVID LAWRENCE FIRMAN ,  COE MILES NICHOLAS

Inventor： COE JOTHAM WADSWORTH ,  GRAY DAVID LAWRENCE FIRMAN ,  COE MILES NICHOLAS

IPC: F16K24/02 ,  F16K15/20 ,  F16K24/04 ,  F16K24/06

CPC classification number: F16K15/20 ,  A63B41/12 ,  A63B2210/50

Abstract: This invention relates to a threaded valved inflation needle designed for controlled inflation or deflation of balls and toys by communicating with standard air sources, inflation methods and pressure monitoring devices. The invention is useful for adjustment and monitoring of internal pressure in balls that utilize a rubber valve of the type that commonly appears in recreational balls. The invention is also useful for controlled inflation of toys that utilize plastic pull out valves for communicating with external air sources. The utility and convenience of the threaded valved inflation needle is further enhanced by a cover designed to hold, protect, and lubricate the threaded valved inflation needle when not in use.

Abstract translation: 本发明涉及一种螺纹阀式充气针头，其设计用于通过与标准空气源，充气方法和压力监测装置进行通信来控制球和玩具的充气或放气。 本发明对于利用通常出现在休闲球中的类型的橡胶阀的球的内部压力的调节和监测是有用的。 本发明对于利用塑料拉出阀用于与外部空气源连通的玩具的受控充气也是有用的。 带螺纹带阀的充气针的实用性和便利性通过设计用于在不使用时保持，保护和润滑带螺纹带阀的充气针的盖来进一步增强。

公开(公告)号：WO2005018622A8

公开(公告)日：2005-04-28

申请号：PCT/IB2004002604

申请日：2004-08-09

Applicant: PFIZER PROD INC ,  COE JOTHAM WADSWORTH ,  O'NEILL BRIAN THOMAS ,  SANDS STEVEN BRADLEY

Inventor： COE JOTHAM WADSWORTH ,  O'NEILL BRIAN THOMAS ,  SANDS STEVEN BRADLEY

IPC: A61K31/195 ,  A61K45/06 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61K31/00

CPC classification number: A61K45/06 ,  A61K31/195 ,  A61K2300/00

Abstract: Pharmaceutical compositions are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an alpha2dela ligand and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

Abstract translation: 公开了用于治疗肥胖，超重状况和强迫性暴饮暴食的药物组合物。 药物组合物由烟碱受体部分激动剂和α2dela配体和药学上可接受的载体的治疗有效组合组成。 还公开了使用这些化合物的方法。

公开(公告)号：WO2003005998A2

公开(公告)日：2003-01-23

申请号：PCT/IB2002/001767

申请日：2002-05-21

Applicant: PFIZER PRODUCTS INC. ,  COE, Jotham, Wadsworth ,  SANDS, Steven, Bradley

Inventor： COE, Jotham, Wadsworth ,  SANDS, Steven, Bradley

IPC: A61K31/00

CPC classification number: A61K31/435 ,  A61K2300/00

Abstract: A pharmaceutical composition and method of modulating colinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emtic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and additions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituarates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD) Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed.

Abstract translation: 一种调节哺乳动物中colinergic功能的药物组合物和方法，包括给药NRPA化合物或其药学上可接受的盐; 和抗呕吐/抗恶心剂或其药学上可接受的盐; 和药学上可接受的载体。 NRPA化合物和抗呕吐/抗恶心呕吐剂的含量使得组合物有效调节胆碱能功能或治疗选自炎症性肠病（包括但不限于溃疡性结肠炎，坏疽性坏疽性坏死症） 焦虑症，恐慌症，抑郁症，双相情感障碍，孤独症，睡眠障碍，时差，肌萎缩性侧索硬化（ALS），痉挛性肌张力障碍，痉挛性肌张力障碍， 认知功能障碍，高血压，贪食症，厌食症，肥胖症，心脏性心律失常症，胃酸分泌过多，溃疡，嗜铬细胞瘤，进行性核上性麻痹，化学依赖性和添加（例如，对尼古丁（和/或烟草制品）的依赖性或成瘾性， 苯二氮卓类，巴比妥类，阿片类或可卡因），头痛，偏头痛，中风，创伤性脑损伤（TBI），强迫症 （OCD），精神病，亨廷顿氏舞蹈症，迟发性运动障碍，运动过度，阅读困难，精神分裂症，多发性梗死性痴呆，年龄相关的认知衰退，癫痫，包括小痴呆症癫痫，老年痴呆症（AD）帕金森病 PD），注意缺陷多动障碍（ADHD）和Tourette综合征。 还公开了使用这些组合物的方法。

公开(公告)号：WO1992018498A1

公开(公告)日：1992-10-29

申请号：PCT/US1992002434

申请日：1992-03-30

Applicant: PFIZER INC. ,  COE, Jotham, Wadsworth ,  FLIRI, Anton, Franz, Josef ,  KANEKO, Takushi ,  LARSON, Eric, Robert

Inventor： PFIZER INC.

IPC: C07D401/04

CPC classification number: C07D239/48 ,  C07D401/04 ,  C07D401/14

Abstract: 2,4-Diaminopyrimidine derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.

Abstract translation: 2,4-二氨基嘧啶衍生物作为治疗癌症的化学治疗剂的增效剂。

公开(公告)号：WO2008065500A3

公开(公告)日：2008-11-13

申请号：PCT/IB2007003604

申请日：2007-11-19

Applicant: PFIZER PROD INC ,  LOWE III JOHN ADAMS ,  SAKYA SUBAS MAN ,  SANNER MARK ALLEN ,  COE JOTHAM WADSWORTH ,  MCHARDY STANTON FURST

Inventor： LOWE III JOHN ADAMS ,  SAKYA SUBAS MAN ,  SANNER MARK ALLEN ,  COE JOTHAM WADSWORTH ,  MCHARDY STANTON FURST

IPC: C07D233/90 ,  A61K31/4164 ,  A61K31/4178 ,  A61P25/00 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12

CPC classification number: C07D403/12 ,  C07D233/90 ,  C07D401/12 ,  C07D413/12

Abstract: The present invention relates to a series of substituted heteroaryl amides of the Formula (I), wherein, R 1 -R 12 groups are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, Including humans, wherein HET is a 5 or 6 membered membered heteroaryl ring optionally substituted by one or more substituents selected from R 5 ; X 1 Is C(=O) Or SO 2 ;. X 2 Is -(C zero -C 1O alkyleneXO) y -(C zero -C 10 alkytene)-, or -(C 3 C 10 cycloalkyl)-(C zero -C 10 alkylene)-(O) y -(C zero H 10 alkylene)-; wherein y is O or 1; X 3 Is -(C zero -C 1O alkylene)-NR 1 R 2 ; -(C 3 -C 10 alkylene)-NR 1 R 2 ; -(C zero -C 10 alkylene)-X 4 or (C 3 -C 10 cycloalkyl)-(C zero -C 10 alkylene)-X 4 ; wherein said cycloalkyl is optional substituted by one or more -OH; X 4 is a nitrogen containing (5-15 membered) heterocydoalkyi or a nitrogen containing (5-15 membered) heteroaryl, each optionally substituted by one or more substituents selected from R5; with the proviso that the 4-15 membered heterocydoalkyi of X 4 is not a 3-aza-bicyclo{3.1.0]hex-6-yl group; Ring A Is a -(C 5 -C 15 ) aryt, -(5-15 membered) heteroaryl or (5-15 membered) heterocydoalkyi.

Abstract translation: 本发明涉及式（I）的一系列取代的杂芳基酰胺，其中R 1 -R 12基团如说明书中所定义，表现出活性 作为甘氨酸转运抑制剂，其药学上可接受的盐，含有它们的药物组合物，以及它们用于增强认知和治疗哺乳动物（包括人）中精神分裂症和其它精神病的阳性和阴性症状的用途，其中HET是5或6 任选被一个或多个选自R 5的取代基取代的多元杂芳基环; C 1 =（O）或SO 2 H 2。 （C 1 -C 6） - （C 1 -C 6 - 亚烷基XO） - （C 0 - （C 1 -C 10烷基） - 或 - （C 3 -C 10环烷基） - （C -C 10亚烷基） - （O） - 亚磺酰基 - （C 1 -C 10亚烷基） - ; 其中y为0或1; X 3是 - （C 1 -C 6 - 亚烷基）-NR 1 R 2， SUP>; - （C 3 -C 10亚烷基）-NR 1 R 2 2; - （C 0〜C 10 - 亚烷基）-X 4或（C 3 -C 3） - 环烷基） - （C 0 -C 10 - 亚烷基）-X 4; 其中所述环烷基任选被一个或多个-OH取代; X 4是含氮（5-15元）杂环烷基或含氮（5-15元）杂芳基，各自任选被一个或多个选自R 5的取代基取代; 条件是X 4的4-15元杂环烷基不是3-氮杂 - 双环{3.1.0]己基-6-基; 环A是 - （C 15 -C 15）芳基， - （5-15元）杂芳基或（5-15元）杂环烷基。